For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
7
views
30
references
 Top references
cited by
7
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      1,036
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Objectives

          The study evaluated the efficacy of thalidomide in prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation (RCCEP).

          Methods

          In this study, patients treated with camrelizumab plus thalidomide or camrelizumab alone were included. The occurrences, onset time, severity of RCCEP and the adverse effect of thalidomide were analysed.

          Results

          A total of 19 patients were enrolled. The incidence of RCCEP in thalidomide group (2/9, 22.2%) was significantly lower than that in camrelizumab group (8/10, 80%). The median onset time of RCCEP was 5 weeks and 4 weeks respectively. The adverse events of thalidomide were mild, and no treatment‐associated interruption was observed.

          Conclusions

          Thalidomide showed a promising in prevention of the RCCEP in patients receiving camrelizumab therapy with an acceptable safety profile.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

          Suzanne Topalian, F. Stephen Hodi, Julie Brahmer … (2012)
          Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kilogram of body weight every 2 weeks. Response was assessed after each 8-week treatment cycle. Patients received up to 12 cycles until disease progression or a complete response occurred. A total of 296 patients received treatment through February 24, 2012. Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity. No maximum tolerated dose was defined. Adverse events consistent with immune-related causes were observed. Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were observed in those with non-small-cell lung cancer, melanoma, or renal-cell cancer. Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients). Responses were durable; 20 of 31 responses lasted 1 year or more in patients with 1 year or more of follow-up. To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochemical analysis was performed on pretreatment tumor specimens obtained from 42 patients. Of 17 patients with PD-L1-negative tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-positive tumors had an objective response (P=0.006). Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.).
          Article 0 comments Cited 2266 times – based on 0 reviews     Review now
          Article has an altmetric score of 457
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

            I. Puzanov, A. Diab, K Abdallah … (2017)
            Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs’ therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. Immunotherapy-related irAEs typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. There is an urgent need for multidisciplinary guidance reflecting broad-based perspectives on how to recognize, report and manage organ-specific toxicities until evidence-based data are available to inform clinical decision-making. The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here we present their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy. Electronic supplementary material The online version of this article (10.1186/s40425-017-0300-z) contains supplementary material, which is available to authorized users.
            Article 0 comments Cited 610 times – based on 0 reviews     Review now
            Article has an altmetric score of 508
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

              Jing Huang, Jianming Xu, Yun Chen … (2020)
              Patients with advanced or metastatic oesophageal squamous cell carcinoma have poor prognosis and few treatment options after first-line therapy. We aimed to assess efficacy and safety of the anti-PD-1 antibody camrelizumab versus investigator's choice of chemotherapy in previously treated patients.
              Article 0 comments Cited 324 times – based on 0 reviews     Review now
              Article has an altmetric score of 64
                Bookmark
                All references

                Author and article information

                Contributors
                Huai‐Dong Cheng: chenghuaidongchd@yeah.net
                Journal
                Journal ID (nlm-ta): Australas J Dermatol
                Journal ID (iso-abbrev): Australas J Dermatol
                Journal ID (doi): 10.1111/(ISSN)1440-0960
                Journal ID (publisher-id): AJD
                Title: The Australasian Journal of Dermatology
                Publisher: John Wiley and Sons Inc. (Hoboken )
                ISSN (Print): 0004-8380
                ISSN (Electronic): 1440-0960
                Publication date (Electronic): 01 March 2022
                Publication date (Print): May 2022
                Volume: 63
                Issue: 2 ( doiID: 10.1111/ajd.v63.2 )
                Pages: 217-221
                Affiliations
                [ 1 ] Department of Oncology The Second Affiliated Hospital of Anhui Medical University Hefei China
                Author notes
                [*] [* ] Correspondence: Dr Huai‐Dong Cheng, Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China. Email: chenghuaidongchd@ 123456yeah.net

                Author information
                https://orcid.org/0000-0001-5649-3025
                Article
                Publisher ID: AJD13812 Other ID: AJD-2021-1725.R1
                DOI: 10.1111/ajd.13812
                PMC ID: 9313837
                PubMed ID: 35229882
                SO-VID: 47f2bfe5-8830-4627-8126-e3691cb4057c
                Copyright © © 2022 The Authors. Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists.
                License:

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                Date revision received : 28 January 2022
                Date received : 25 December 2021
                Date accepted : 08 February 2022
                Page count
                Figures: 0, Tables: 2, Pages: 221, Words: 3771
                Funding
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: No. 81872504
                Categories
                Subject: Original Research
                Subject: Original Research
                Custom metadata
                source-schema-version-number 2.0
                cover-date May 2022
                details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:25.07.2022

                Keywords: camrelizumab,reactive cutaneous capillary endothelial proliferation,thalidomide
                Data availability:
                Keywords: camrelizumab, reactive cutaneous capillary endothelial proliferation, thalidomide

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content1,036

                See all similar

                Cited by7

                See all cited by

                Most referenced authors802

                See all reference authors